Literature DB >> 1504732

Combined dose-ratio analysis of cholecystokinin receptor antagonists, devazepide, lorglumide and loxiglumide in the guinea-pig gall bladder.

L A Bishop1, V P Gerskowitch, R A Hull, N P Shankley, J W Black.   

Abstract

1. Interactions between cholecystokinin octapeptide (CCK-8) and CCKA-receptor antagonists derived from benzodiazepines (devazepide) and glutamic acid (lorglumide and loxiglumide) have been examined in an improved bioassay using the guinea-pig, isolated, gall bladder preparation. 2. The presence of CCKB-receptors in the assay was provisionally-ruled out on the basis of the low potency of pentagastrin in the assay. By applying analyses of both agonism and antagonism, pentagastrin was shown to behave as a partial agonist at the CCKA-receptor. 3. Devazepide, lorglumide and loxiglumide behaved as simple competitive antagonists of CCKA-receptors and pKB values of 9.98, 7.59 and 7.07 were estimated, respectively. 4. Application of a combined dose-ratio analysis to the interactions between CCK-8 and combinations of devazepide/lorglumide and devazepide/loxiglumide indicated that these molecules behave as syntopic, competitive, antagonists at the CCKA-receptor. 5. We conclude that the guinea-pig gall bladder assay contains a homogeneous population of CCKA-receptors and offer an explanation for the differences between our results and those obtained recently by Maubach et al. (1991) which were taken as preliminary evidence for CCKA-receptor heterogeneity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1504732      PMCID: PMC1907434          DOI: 10.1111/j.1476-5381.1992.tb14293.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

1.  Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin.

Authors:  B E Evans; M G Bock; K E Rittle; R M DiPardo; W L Whitter; D F Veber; P S Anderson; R M Freidinger
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

2.  Evidence that cholecystokinin octapeptide (CCK-8) acts as a potent, full agonist on gastrin receptors for acid secretion in the isolated mouse stomach: lack of antagonism by the specific CCK antagonist asperlicin.

Authors:  V J Lotti; R S Chang; P J Kling; D J Cerino
Journal:  Digestion       Date:  1986       Impact factor: 3.216

Review 3.  The autonomic pharmacology of the bladder.

Authors:  N Taira
Journal:  Annu Rev Pharmacol       Date:  1972       Impact factor: 13.820

4.  Operational models of pharmacological agonism.

Authors:  J W Black; P Leff
Journal:  Proc R Soc Lond B Biol Sci       Date:  1983-12-22

5.  Correlation between log POCT/H2O and pKB estimates for a series of muscarinic and histamine H2-receptor antagonists.

Authors:  N P Shankley; J W Black; C R Ganellin; R C Mitchell
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

6.  The affinity and efficacy of onium salts on the frog rectus abdominis.

Authors:  R B Barlow; N C Scott; R P Stephenson
Journal:  Br J Pharmacol Chemother       Date:  1967-09

7.  Further analysis of anomalous pKB values for histamine H2-receptor antagonists on the mouse isolated stomach assay.

Authors:  J W Black; P Leff; N P Shankley
Journal:  Br J Pharmacol       Date:  1985-11       Impact factor: 8.739

8.  An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation.

Authors:  J W Black; P Leff; N P Shankley; J Wood
Journal:  Br J Pharmacol       Date:  1985-02       Impact factor: 8.739

9.  Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonist.

Authors:  I Setnikar; M Bani; R Cereda; R Chisté; F Makovec; M A Pacini; L Revel; L C Rovati; L A Rovati
Journal:  Arzneimittelforschung       Date:  1987-06

10.  Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.

Authors:  F Makovec; M Bani; R Cereda; R Chisté; M A Pacini; L Revel; L A Rovati; L C Rovati; I Setnikar
Journal:  Arzneimittelforschung       Date:  1987-11
View more
  7 in total

1.  Pharmacological evidence for putative CCK(1) receptor heterogeneity in human colon smooth muscle.

Authors:  M F Morton; E A Harper; I A Tavares; N P Shankley
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

2.  2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP)--a selective cholecystokinin CCKA-receptor antagonist.

Authors:  R A Hull; N P Shankley; E A Harper; V P Gerkowitch; J W Black
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

3.  Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle.

Authors:  G S Baxter; O E Murphy; T P Blackburn
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

4.  Control of gallbladder contractions by cholecystokinin through cholecystokinin-A receptors on gallbladder interstitial cells of Cajal.

Authors:  Dan Xu; Bao-Ping Yu; He-Sheng Luo; Ling-Dan Chen
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

5.  Application of a model to explore interspecies differences in acetylcholine M-receptor-stimulated gastric acid secretion.

Authors:  N J Welsh; N P Shankley; J W Black
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

6.  Mediation by CCKB receptors of the CCK-evoked hyperaemia in rat gastric mucosa.

Authors:  A Heinemann; M Jocic; U Holzer-Petsche; G Pethö; B M Peskar; D C Horwell; P Holzer
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

7.  The use of receptor desensitization to analyse CCKA and CCKB/gastrin receptors coupled to contraction in guinea-pig stomach muscle.

Authors:  L A Bishop; V P Gerskowitch; R A Hull; N P Shankley; J W Black
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.